enGene Therapeutics ENGN
NASDAQ ENGN
$1.98 -0.02 (-1.00%)
At close: Oct 1, 2026 · 4:00 PM EDT

enGene Therapeutics (ENGN) Preferred Stock Liabilities (2022 - 2023)

Updated

enGene Therapeutics (ENGN) posted Preferred Stock Liabilities of $53.12 million for fiscal Q2 2023 (quarter ended Apr 30, 2023), unchanged from the prior quarter.

Analysis

enGene Therapeutics (ENGN) Preferred Stock Liabilities (2022 - 2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 enGene Therapeutics 134.03 Mn 134.03 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Apr 30, 2023 53.12 Mn
Jan 31, 2023 53.12 Mn
Oct 31, 2022 53.12 Mn
API Access

enGene Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=ENGN&period=max&api_key=YOUR_API_KEY